生命科学资讯
生物技术与制药领域的最新动态
PIKFYVE抑制在多种ALS模型中有助于缓解疾病
PIKFYVE inhibition mitigates disease in models of diverse forms of ALS
美国奶牛中的H5N1禽流感疫情能否得到控制?
Can H5N1 avian influenza in dairy cattle be contained in the US?
Illumina发布十亿细胞图谱,试图破解生物学中人工智能的数据瓶颈 - 2分钟医学
Illumina’s billion cell atlas tries to solve artificial intelligence’s data bottleneck in biology - 2 Minute Medicine
Illumina十亿细胞图谱试图破解AI在生物学中的数据瓶颈——2分钟医学
Illumina’s billion cell atlas tries to solve artificial intelligence’s data bottleneck in biology - 2 Minute Medicine
先驱转录因子Nr5a2的过表达促进小鼠体细胞核移植胚胎的发育
Overexpression of the pioneer transcription factor Nr5a2 promotes the development of mouse somatic cell nuclear transfer embryos
细胞疗法生物加工市场即将迎来繁荣 |• 龙沙 • 赛默飞世尔科技 - openPR.com
Cell Therapy Bioprocessing Market Is Going to Boom |• Lonza • Thermo Fisher Scientific - openPR.com
早期抗逆转录病毒治疗启动后24周,HIV特异性CD8+ T细胞增殖反应与后续病毒库减少相关
HIV-specific CD8+ T-cell proliferative response 24 weeks after early antiretroviral therapy initiation is associated with the subsequent reduction in the viral reservoir
结肠癌细胞不对称分裂的稳健评估
Robust assessment of asymmetric division in colon cancer cells
百时美施贵宝投资Janux的“掩蔽”T细胞接合剂技术。
Bristol Myers buys into Janux’s ‘masked’ T cell engagers
人类嗅觉受体OR6A2中气味分子可逆共价键的结构解码
Structural decoding of reversible covalent linkage of odorants in human olfactory receptor OR6A2
Or5v1/Olfr110被鉴定为氧脂素受体及抗肥胖靶点
Identification of Or5v1/Olfr110 as an oxylipin receptor and anti-obesity target
脂肪酸气味检测机制:II类嗅觉受体介导的分子洞察
Mechanistic insights into fatty acid odor detection mediated by class II olfactory receptors
百时美施贵宝与Janux达成8.5亿美元实体瘤T细胞衔接器协议。
BMS pens $850M solid tumor pact with T-cell engager biotech Janux
百时美施贵宝与Janux达成T细胞接合剂协议,首付款5000万美元。
Bristol Myers signs deal with Janux on T cell engager for $50M upfront
Zacks行业展望聚焦Doximity、10x Genomics与Omnicell——雅虎财经报道
Zacks Industry Outlook Highlights Doximity, 10x Genomics and Omnicell - Yahoo Finance
扎克斯行业展望聚焦Doximity、10x Genomics与Omnicell - 雅虎财经新西兰版
Zacks Industry Outlook Highlights Doximity, 10x Genomics and Omnicell - Yahoo Finance New Zealand
肢体再生的细胞逻辑
The cellular logic of limb regeneration
诺和诺德剥离糖尿病资产给Aspect,细胞疗法领域战略收缩。
Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat
诺瓦细胞科技报告新型FPR2激动剂
Novacell Technology reports new FPR2 agonists